Helix BioPharma Corp. (TSX:HBP, OTC PINK:HBPCD, FRANKFURT:HBP0), a clinical-stage oncology company, today reported financial results for the three- and nine-month periods ended April 30, 2026, highlighting a reduced net loss and improved cash position following a private placement. The company is focused on advancing its lead candidate, L-DOS47, toward the clinic and pursuing a U.S. exchange listing to expand access to capital.
For the nine months ended April 30, 2026, Helix incurred a net loss of $2.374 million, or $0.03 per common share, compared to a net loss of $4.255 million, or $0.08 per common share, for the same period in 2025. The decrease was primarily due to lower research and development expenses and the closure of the LDOS006 clinical study, partially offset by higher operating, general, and administrative costs related to accounting, tax, legal, and consulting fees.
Cash and cash equivalents stood at $2.842 million as of April 30, 2026, a significant increase from $65,000 as of July 31, 2025. During the quarter, the company received $3.673 million in cash proceeds from a private placement of unsecured convertible debentures. The debentures, issued subsequent to quarter-end, bear interest at 25% per annum and mature 14 months from the closing date of July 27, 2027. The principal is convertible at $1.42 per common share, with accrued interest convertible at the greater of $1.42 or the 5-day volume-weighted average price less the TSX-permitted discount.
“Since the beginning of the year, our focus has been on securing the capital necessary to support Helix’s near-term operating and development objectives,” said Thomas Mehrling, MD, PhD, Chief Executive Officer. “With the successful completion of our recent private placement, we have made substantial progress toward our objective of establishing approximately twelve months of operating runway.”
Mehrling added that the financing strengthens the company’s ability to execute strategic priorities, including preparations for a U.S. exchange listing to broaden its investor base and increase access to capital markets. Helix is working with legal advisors on filing a base shelf prospectus and is in discussions with prospective investment banking partners.
The company’s pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased therapy sensitivity. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC). Helix also advances two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA, an oral gemcitabine prodrug.
The interim financial statements and management’s discussion and analysis are available on the company’s profile at www.sedarplus.ca and on its website at https://www.helixbiopharma.com/filings-and-financials/.
